VANCOUVER, BC--(Marketwire - April 21, 2008) - TapImmune Inc. (OTCBB: TPIM) (FRANKFURT: GX1A) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies.
